Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European drug-induced liver injury network [PRO-EURO-DILI-NET]

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378271%3A_____%2F21%3A00546144" target="_blank" >RIV/68378271:_____/21:00546144 - isvavai.cz</a>

Výsledek na webu

<a href="http://hdl.handle.net/11104/0322792" target="_blank" >http://hdl.handle.net/11104/0322792</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jhep.2021.06.021" target="_blank" >10.1016/j.jhep.2021.06.021</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European drug-induced liver injury network [PRO-EURO-DILI-NET]

Popis výsledku v původním jazyce

Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing.

Název v anglickém jazyce

Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European drug-induced liver injury network [PRO-EURO-DILI-NET]

Popis výsledku anglicky

Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/LTC19040" target="_blank" >LTC19040: Rozvinuté fyzikální metody v studiích hepatotoxicity</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Hepatology

ISSN

0168-8278

e-ISSN

1600-0641

Svazek periodika

75

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

25

Strana od-do

935-959

Kód UT WoS článku

000701940000003

EID výsledku v databázi Scopus

2-s2.0-85112427042